Investigation Commenced for Applied Therapeutics, Inc. by Levi & Korsinsky

New York, NY / Accesswire / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. (“Applied Therapeutics, Inc.”) (NASDAQ:APLT) concerning possible violations of federal securities laws.

Press Release by Applied Therapeutics

Applied Therapeutics issued a press release on November 27, 2024, announcing that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.

Investigation Details

The investigation by Levi & Korsinsky aims to uncover any possible violations of federal securities laws by Applied Therapeutics, Inc. This news has caused uncertainty among investors and stakeholders of the company.

Impact on Me

As an investor in Applied Therapeutics, Inc., this news may have a direct impact on my investment portfolio. The uncertainty surrounding the investigation and the FDA’s Complete Response Letter could lead to volatility in the stock price of the company, potentially affecting my financial well-being.

Impact on the World

The investigation of Applied Therapeutics, Inc. by Levi & Korsinsky and the FDA’s Complete Response Letter for govorestat could have broader implications in the pharmaceutical industry. The outcome of this investigation and the FDA’s decision may influence future drug development processes and regulations, shaping the landscape of healthcare globally.

Conclusion

In conclusion, the investigation of Applied Therapeutics, Inc. by Levi & Korsinsky and the FDA’s Complete Response Letter for govorestat have created waves in the pharmaceutical industry. It is essential for investors to stay informed and monitor the developments closely to make informed decisions about their investments.